Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Rapid whole-genome sequencing (rWGS) delivered a genetic diagnosis in 45% of hospitalized children with unexplained neurologic conditions — and changed clinical management in two-thirds of those diagnosed. A new retrospective study from Mayo Clinic is the first to evaluate rWGS across inpatient settings beyond the ICU, showing it's just as valuable on the general pediatric floor. Results came back in as little as 4 days.
Rapid whole-genome sequencing (rWGS) is proving its worth far beyond the ICU. A retrospective study published in JAMA Neurology found that rWGS established a genetic diagnosis in 45% of 175 children hospitalized with unexplained neurologic presentations at Mayo Clinic — and in two-thirds of those diagnosed, the results directly changed how the child was treated. Crucially, this is the first known study to evaluate rWGS across all inpatient pediatric neurology settings, including the general floor, where the technology has rarely been used.
The impact was real and immediate. In one case, a child undergoing a child abuse investigation for a femur fracture was instead diagnosed with osteogenesis imperfecta after sequencing identified a COL1A1 variant — ending the abuse probe and starting targeted therapy. In another, a child with refractory epilepsy received enzyme replacement therapy delivered directly to the brain after sequencing pinpointed the cause of a progressive brain disease.
By the Numbers:
Why it matters: Expanding rWGS beyond the ICU could transform care for children with mysterious neurologic conditions, but cost and access remain major barriers. A pending federal bill — the Genomic Answers for Children's Health Act — could extend Medicaid coverage to all inpatient and outpatient settings, potentially opening the door for thousands more families.
